ReviewVaccines2022
From Concept to Clinical Product: A Brief History of the Novel
Review in Vaccines, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 30 citations in OpenAlex.
- Review
- Development of a NovelVaccines · 2026Article
- Article
- Conserved antigens for enteric vaccines.Vaccine · 2025Review
- A Candidate AcVaccines · 2025Article
- Safety, Tolerability, and Immunogenicity of the InvaplexVaccines · 2025Article
- Development and Characterization of a 13-Plex Binding Assay to DetectOpen forum infectious diseases · 2024Article
- Outer membrane protein C is a protective and unique vaccine antigen against Shigella flexneri 3a.Scientific reports · 2024Article
- Evaluation of a QuadrivalentVaccines · 2024Article
- TestingPharmaceutics · 2024Article
- The 2022 Vaccines Against Shigella and Enterotoxigenic Escherichia coli (VASE) Conference: Summary of breakout workshops.Vaccine · 2024Article
- Optimizing Vaccine Trials for Enteric Diseases: The Enterics for Global Health (EFGH)Open forum infectious diseases · 2024Article
- Shigella virulence protein VirG is a broadly protective antigen and vaccine candidate.NPJ vaccines · 2024Article
- Designing a multi-epitope vaccine againstFrontiers in genetics · 2024Article
- A rhesus macaque intragastric challenge model for evaluating the safety, immunogenicity, and efficacy of live-attenuatedFrontiers in microbiology · 2024Article
- Reassessing potential economic value and health impact of effectiveBulletin of the World Health Organization · 2024Article
- Development of themSphere · 2023Article
- Article
- A Shigella flexneri 2a synthetic glycan-based vaccine induces a long-lasting immune response in adults.NPJ vaccines · 2023Article
- Toward aInternational journal of molecular sciences · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.